EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

Sheridan M Hoy

Targeted Oncology · 2026-05 · 21 (3) · 447-457

DOI: 10.1007/s11523-026-01210-7 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Targeted Oncology, online erschienen am 21.04.2026. Verfasst von Sheridan M Hoy. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Isatuximab (isatuximab-irfc; SARCLISA®) is an anti-CD38 monoclonal antibody approved in the EU and the USA for use in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adults with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (ASCT). In a phase III study in this patient population, isatuximab–bortezomib–lenalidomide–dexamethasone significantly prolonged progression-free survival (PFS) and generally improved the depth of tumour response versus bortezomib–lenalidomide–dexamethasone. Overall survival (OS) data were immature at the time of this analysis. Health-related quality of life was not affected by adding isatuximab to bortezomib–lenalidomide–dexamethasone. Only a slight increase in toxicity resulted from the addition of isatuximab to bortezomib–lenalidomide–dexamethasone, with the safety findings from the study consistent with the known safety profile of isatuximab–bortezomib–lenalidomide–dexamethasone. Although further interim and final PFS and OS data are awaited, current evidence indicates that isatuximab–bortezomib–lenalidomide–dexamethasone is a useful addition to the treatment options available for adults with NDMM who are ineligible for ASCT. A successful strategy for improving clinical outcomes in patients with multiple myeloma (MM) is combining drugs with synergistic mechanisms of action and overlapping toxicities. Isatuximab (isatuximab-irfc; SARCLISA®) is a monoclonal antibody targeting CD38, a protein highly expressed on MM cells. In combination with bortezomib, lenalidomide and dexamethasone, isatuximab prolonged progression-free survival, generally improved the depth of tumour response and did not affect health-related quality of life versus bortezomib, lenalidomide and dexamethasone in adults with newly diagnosed MM (NDMM) who are ineligible to receive a transplant of stem cells from their own body. The addition of isatuximab to bortezomib–lenalidomide–dexamethasone resulted in only a slight increase in toxicity, with the study’s safety findings consistent with the known safety profile of isatuximab–bortezomib–lenalidomide–dexamethasone. The combination of isatuximab with bortezomib, lenalidomide and dexamethasone is thus a useful addition to the treatment options available for adults with transplant-ineligible NDMM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, Monoclonal, HumanizedHumansBortezomib

Substanzen

Antibodies, Monoclonal, HumanizedisatuximabBortezomib

Autor:innen und Institutionen

  • Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Zitieren

APA

Hoy, S. M. (2026). Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma. Targeted Oncology, 21(3), 447-457. https://doi.org/10.1007/s11523-026-01210-7

Vancouver

Hoy SM. Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma. Targeted Oncology. 2026;21(3):447-457. doi:10.1007/s11523-026-01210-7

BibTeX
@article{Hoy2026,
  author = {Hoy, Sheridan M},
  title = {Isatuximab: A Review in Transplant-Ineligible Newly Diagnosed Multiple Myeloma},
  journal = {Targeted Oncology},
  year = {2026},
  volume = {21},
  number = {3},
  pages = {447--457},
  doi = {10.1007/s11523-026-01210-7}
}
Kostenlos starten →